How an understanding of the regulatory framework is essential for the future generations of cell and gene therapy professionals.

The cell and gene therapy industry has amazing statistics. But to reach the next level, the industry must address its talent gap.

The UK’s “sovereignty” debate does not end with an agreed UK-EU relationship. It extends to all trading partners...

The US opioid crisis has claimed the lives of hundreds of thousands. We examine pharma’s role.

Can’t offer an “affordable” price? Then say goodbye to market exclusivity.

The Jefferson Institute for Bioprocessing is up and running after just two years. How did they do it? And what courses are on offer?

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain.

Should pharma companies transition from developing, manufacturing and pricing “drugs” to promoting “health”?

Meet CPI: the UK not-for-profit dedicated to de-risking innovation.

With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.